Wednesday, February 13
8:00 – 9:40 am
Personalized Oncology – Fulfilling the Promise for Today’s Patients
In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology.Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs.Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future.
Topics for discussion include:
- Scientific approaches to treating cancer, involving deep molecular profiling and pathway analysis of individual tumors to design custom treatments, and then monitoring the tumor’s response to therapy using sequential biopsies and CTCs.
- Open science initiatives to rapidly learn and refine the clinically actionable, molecular subtypes of cancer and how to treat them.
- New models of translational research that can slash the time and cost of developing highly targeted agents for rare subtypes.
- Efficient systems to enable patients affordable investigational drugs for testing in small proof-of-concept studies.
- Complementary computational approaches to identifying cancer pathways, targets, and subtypes.
- Pragmatic approaches for capturing treatment and outcomes data from every cancer patient, to validate and extend the knowledge of molecular subtypes and treatments.
- The industry ecosystem and what’s needed to deliver personalized oncology services at scale.
- Moderator: Marty Tenenbaum, Ph.D., Founder and Chairman, Cancer Commons; Prominent AI Researcher; Cancer Survivor
- Tony Blau, M.D., Professor, Department of Medicine/Hematology and Adjunct Professor, Department of Genome Sciences, University of Washington; Attending Physician, Seattle Cancer Care Alliance; Co-Director, Institute for Stem Cell and Regenerative Medicine, University of Washington and the Program for Stem and Progenitor Cell Biology at the UW/FHCRC Cancer Consortium; Founder and Scientific Officer, Partners in Personal Oncology
- Sarah Greene, Executive Director, Cancer Commons
- Mikhail Gishizky, Ph.D., Entrepreneurial Pharmaceutical and Biotechnology Executive
- Jane Reese-Coulbourne, MS, ChE, Executive Director, Reagan-Udall Foundation for the FDA; Former Board Chair, Lung Cancer Alliance; Cancer Survivor
- Anil Sethi, CEO, Pinch Bio; HL7 Pioneer and Health Informatics Entrepreneur
- Joshua Stuart, Ph.D., Associate Professor, Department of Biomolecular Engineering, University of California Santa Cruz
Thursday, February 14
8:00 – 9:40 am
Plenary Keynote Panel: Emerging Technologies & Industry Perspectives
This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included.
Moderator: Harry Glorikian, Managing Partner, Scientia Advisors, LLC
Gregory Parekh, Ph.D., CEO, Biocartis
Kevin Bobofchak, Ph.D., Pathway Studio Product Manager, Elsevier
Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex Corporation
Gary Kennedy, Founder & CEO, Remedy Informatics
Harry Glorikian, Managing Partner, Scientia Advisors, LLC
Lynn R. Zieske, Ph.D., Vice President, Commercial Solutions, Singulex, Inc.